ArticleACS applied materials & interfaces2022
Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using
Article in ACS applied materials & interfaces, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors.Annals of medicine · 2025Pooled it
- Recent advances in biomedical applications of lyotropic liquid crystals.Acta pharmaceutica Sinica. B · 2026Review
- Liquid crystalline system for drug delivery: structural insights, preparation techniques and translational potential.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer.ACS biomaterials science & engineering · 2026Article
- Hyaluronic acid capped cubosomes co-loaded with antitumor agents towards the treatment of colorectal cancer.Scientific reports · 2025Article
- Caulerpin Delivery via Pluronic-Free Cubosomes: Unlocking the Therapeutic Potential of a Pigment from an Invasive Marine Algae.Molecular pharmaceutics · 2025Article
- Engineering and targeting potential of CAR NK cells in colorectal cancer.Chinese medical journal · 2025Review
- Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems.Medical oncology (Northwood, London, England) · 2025Review
- Surface-engineered bio-manufactured gas vesicles for multimodal imaging of glioma.Journal of nanobiotechnology · 2025Article
- Current Status and Future Prospects of Lyotropic Liquid Crystals as a Nanocarrier Delivery System for the Treatment of Cancer.AAPS PharmSciTech · 2025Review
- Unraveling the Pivotal Role of Nanovesicle Drug Delivery Systems in Colorectal Cancer: A New Paradigm in Therapeutics.Current pharmaceutical design · 2025Review
- Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications.ACS applied bio materials · 2024Review
- Cubosomal nanoformulation increaseTherapeutic delivery · 2024Article
- Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle.Nanoscale · 2024Article
- Recent Advances in Antibacterial Coatings to Combat Orthopedic Implant-Associated Infections.Molecules (Basel, Switzerland) · 2024Review
- Review
- Composite Microgels Loaded with Doxorubicin-Conjugated Amine-Functionalized Zinc Ferrite Nanoparticles for Stimuli-Responsive Sustained Drug Release.International journal of nanomedicine · 2024Article
- Polymeric Micelle-Based Nanogels as Emerging Drug Delivery Systems in Breast Cancer Treatment: Promises and Challenges.Current drug targets · 2024Review
- Assessment of an Anticancer Effect of the Simultaneous Administration of MM-129 and Indoximod in the Colorectal Cancer Model.Cancers · 2023Article
- Applications of Curcumin and Its Nanoforms in the Treatment of Cancer.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Nanomedicines, while having been approved for cancer therapy, present many challenges such as low stability, rapid clearance, and nonspecificity leading to off-target toxicity. Cubosomes are porous lyotropic liquid crystalline nanoparticles that have shown great premise as drug delivery vehicles; however, their behavior
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.